ANI Pharmaceuticals (NASDAQ:ANIP) SVP Sells $157,590.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Ori Gutwerg sold 2,060 shares of the company’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $76.50, for a total value of $157,590.00. Following the completion of the transaction, the senior vice president directly owned 84,782 shares in the company, valued at approximately $6,485,823. This trade represents a 2.37% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

ANI Pharmaceuticals Stock Performance

NASDAQ ANIP opened at $74.04 on Friday. The stock has a fifty day simple moving average of $79.66 and a 200-day simple moving average of $85.93. The company has a current ratio of 2.71, a quick ratio of 2.19 and a debt-to-equity ratio of 1.11. The stock has a market cap of $1.66 billion, a PE ratio of 22.04 and a beta of 0.52. ANI Pharmaceuticals, Inc. has a twelve month low of $56.71 and a twelve month high of $99.50.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Barclays assumed coverage on shares of ANI Pharmaceuticals in a research note on Tuesday, December 9th. They issued an “overweight” rating and a $100.00 price target on the stock. Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Guggenheim lifted their target price on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a report on Friday, January 16th. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research report on Monday, December 29th. Six investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $103.43.

Institutional Trading of ANI Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. Pacer Advisors Inc. increased its holdings in shares of ANI Pharmaceuticals by 1,821.1% in the 4th quarter. Pacer Advisors Inc. now owns 79,919 shares of the specialty pharmaceutical company’s stock valued at $6,309,000 after acquiring an additional 75,759 shares during the last quarter. Invesco Ltd. raised its position in shares of ANI Pharmaceuticals by 26.0% during the 4th quarter. Invesco Ltd. now owns 189,836 shares of the specialty pharmaceutical company’s stock worth $14,986,000 after acquiring an additional 39,178 shares in the last quarter. XTX Topco Ltd purchased a new stake in ANI Pharmaceuticals during the fourth quarter worth approximately $1,243,000. Susquehanna Portfolio Strategies LLC purchased a new stake in ANI Pharmaceuticals during the fourth quarter worth approximately $906,000. Finally, Tang Capital Management LLC boosted its holdings in ANI Pharmaceuticals by 51.6% in the fourth quarter. Tang Capital Management LLC now owns 481,437 shares of the specialty pharmaceutical company’s stock valued at $38,005,000 after purchasing an additional 163,937 shares in the last quarter. 76.05% of the stock is owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.